JP Morgan Chase
ALZN icon

JP Morgan Chase’s Alzamend Neuro ALZN Stock Holding History

JP Morgan Chase’s Portfolio ALZN Stock Details ALZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Hold
0
– -$12 – 7497
2023
Q3 		– Hold
0
– – – 7262
2021
Q4 		– Sell
-1
Closed -$3K – 6606
2021
Q3 		$3K Buy
+1
New +$5.5K ﹤0.01% 6281

Other funds holding ALZN

Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HIA
Harbor Investment Advisory Lutherville, Maryland $1.43B AUM 30.71% 1-Year Est. Return

JP Morgan Chase's ALZN Position: Q4 2023 in Review

JP Morgan Chase held its Alzamend Neuro (ALZN) position steady in Q4 2023 at 0 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7497.

JP Morgan Chase first reported a position in ALZN in Q3 2021 and has held it in 1 quarter since. The position peaked at $3K in Q3 2021. 14 funds tracked by Wall St. Rank hold ALZN as of Q4 2023.

  • JP Morgan Chase held 0 shares of Alzamend Neuro worth $0 as of Q4 2023.
  • JP Morgan Chase left its Alzamend Neuro share count unchanged in Q4 2023.
  • Alzamend Neuro made up ﹤0.01% of JP Morgan Chase's portfolio in Q4 2023, its #7497 holding.
  • JP Morgan Chase first reported a position in Alzamend Neuro in Q3 2021 and has held it in 1 quarter since.
  • JP Morgan Chase's Alzamend Neuro position peaked at $3K in Q3 2021.
  • 14 funds tracked by Wall St. Rank held Alzamend Neuro as of Q4 2023.

Based on JP Morgan Chase's 13F filing for Q4 2023, filed 12 Feb 2024.